Inhibitors of Chk1 (prexasertib, SRA737) are currently being evaluated as potential cancer therapeutics either as monotherapy or in combination with standard of care chemotherapy drugs and ionizing radiation [21, 22]. Here, CHEK1 is linked to cancer.